Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Cefoxitin
Drug ID BADD_D00393
Description Cefoxitin is a semi-synthetic, broad-spectrum cepha antibiotic for intravenous administration. It is derived from cephamycin C, which is produced by Streptomyces lactamdurans.
Indications and Usage For the treatment of serious infections caused by susceptible strains microorganisms.
Marketing Status approved
ATC Code J01DC01
DrugBank ID DB01331
KEGG ID D02345
MeSH ID D002440
PubChem ID 441199
TTD Drug ID D02VFC
NDC Product Code 25021-111; 25021-110; 0143-9876; 44567-245; 66288-4100; 0143-9877; 44567-246; 44567-247; 0143-9878; 25021-109
UNII 6OEV9DX57Y
Synonyms Cefoxitin | MK-306 | MK 306 | MK306 | Cefoxitin Sodium | Sodium, Cefoxitin | Mefoxin | Méfoxin | Mefoxitin
Chemical Information
Molecular Formula C16H17N3O7S2
CAS Registry Number 35607-66-0
SMILES COC1(C2N(C1=O)C(=C(CS2)COC(=O)N)C(=O)O)NC(=O)CC3=CC=CS3
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tenderness08.01.08.005--Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombophlebitis24.01.02.001--Not Available
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Tremor17.01.06.002--
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
Urticaria10.01.06.001; 23.04.02.001--
Vaginal infection21.14.02.002; 11.01.10.002--
Vomiting07.01.07.003--
Vulvovaginal candidiasis21.14.02.003; 11.03.03.005--Not Available
Tubulointerstitial nephritis20.05.02.002--Not Available
Blood urea nitrogen/creatinine ratio increased13.13.01.014--Not Available
Haemorrhage24.07.01.002--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Induration08.01.03.020--Not Available
Renal impairment20.01.03.010--Not Available
Vulvovaginal mycotic infection11.03.05.004; 21.14.02.004--Not Available
Bone marrow failure01.03.03.005--
Acute kidney injury20.01.03.016--
Candida infection11.03.03.021--
Vulvovaginal inflammation21.14.02.014--Not Available
The 3th Page    First    Pre   3    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene